The Zionist Supremacist-derived sanctions against Iran over its non-existent “atom bomb,” has caused a shortage of critical medicines from reaching that nation, Press TV has reported.
“The United States has declared war on Iran – economic war by means of sanctions which threaten the lives of Iranians who are forced to depend on Western-manufactured pharmaceuticals to fight cancer and other life-threatening diseases,” Press TV said in a new article.
“Initiated by the Zionist lobby AIPAC in 1995, the U.S. sanctions, which arguably constitute an act of war, fall under the auspices of the U.S. Department of the Treasury’s Office of Terrorism and Financial Intelligence (TFI), originally established by the Bush administration to combat terrorist financing.
“Sanctions are now managed by David S. Cohen, undersecretary for terrorism and financial intelligence; Daniel L. Glaser, assistant secretary for terrorist financing; and, Adam J. Szubin, director of the office of foreign-asset control, all bureaucrats with careers spanning the administrations of several U.S. presidents,” Press TV continued, although failing to point out that all three of these people are Jewish Supremacists who form part of the controlled U.S. government.
“ This troika of tyranny, referred to as ‘America’s sanction cops,’ has been working for almost ten years with the U.S. Congress, under constant pressure from the Zionist regime, to design ever tougher sanctions against Iran,” Press TV continued.
The sanctions have also succeeded in deterring Western pharmaceutical companies from undertaking business transactions for medicines greatly needed in Iran, despite the Washington regime’s official, but not legally binding, law to the contrary: the Iran Freedom and Counter-Proliferation Act of 2012 Section 1244 (e), seems very clear in its humanitarian exception for medicine: ‘The President may not impose sanctions under this section with respect to any person for conducting or facilitating a transaction for the sale of agricultural commodities, food, medicine, or medical devices to Iran or for the provision of humanitarian assistance to the people of Iran.’
“However in reality, the complexity of the U.S. sanction regimen and the severity of the penalties, which range up to fines of USD $1 million and imprisonment up to 20 years, have discouraged the profit-hungry U.S. pharmaceutical manufacturers from risking their bottom right corners to do what is morally right,” Press TV continued.
“In one instance, a representative from an Iranian pharmaceutical firm flew to Paris with documentation confirming the legality of a business transaction only to be told by the French banker, ‘Even if you bring a letter from the French president himself saying it is OK to do so, we will not risk this.’”
Iran, whose pharmaceutical sector amounts to some USD$3 billion per year, imports roughly 30% of its medication, and is relying increasingly on China and India as U.S. sanctions close the door to business with American and European drug firms, whose exports to Iran fell 30% in 2012.
In some cases, finding substitute drugs to fight certain diseases, such as hemophilia, cancer or multiple sclerosis, is impossible because heavily guarded patents make them unavailable except from Western sources.
“The net result for patients in Iran is that it may be virtually impossible for them to obtain critical live-saving medications, which means effectively that the U.S. sanctions have pronounced a death sentence upon them.”
